New approaches to drug regulation and reimbursement are needed to improve access to innovation, advance patients’ rights and ensure patients are involved in policy making and regulatory processes, according to speakers at the 11th European Patients’ Rights day, held in Brussels earlier this month
A comprehensive Enhanced Recovery After Surgery (ERAS) programme implemented at US healthcare provider Kaiser Permanente’s 20 Northern California medical centres involving nearly 9,000 patients, resulted in a one-third reduction in postoperative complication rates and a 21 per cent reduction in prescriptions of opioid painkillers
A handheld tablet device is helping heart failure patients to manage their disease, according to research presented at the European Society of Cardiology meeting EuroHeartCare in Jonkoping, Sweden on Saturday (20 May)
Nearly half of older adults in Sweden take ten or more medications in their last months of life, often receiving drugs of questionable benefit, according to the first study conducted on the burden of end-of-life medications across an entire population
People are dying from preventable causes at rates higher than expected, according to the first-ever global study, which has uncovered massive inequity of access to, and quality of health care among and within countries, and concludes people are dying from causes with well-known treatments
Leading funders of clinical research around the world say they will require grant holders to register trials in advance and to publish data in full, regardless of whether the results are positive or not
The ICT sector has tripled in value-added in the last 20 years. There has been growth in Europe, with 5.7M jobs in 2014, but the EU is behind other economies
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.